Publications by authors named "R Snijder"
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients with anaemia of chronic kidney disease may lead to increased ESA doses to achieve target haemoglobin levels; however, elevated doses may be associated with increased mortality. Furthermore, patients with hyporesponsiveness to ESAs have poorer clinical outcomes than those who respond well to ESAs. Incidence and clinical characteristics of patients with ESA hyporesponsiveness were explored in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- - PIONEER is a European initiative that combines the efforts of 34 organizations across 9 countries to enhance prostate cancer screening, diagnosis, and treatment using big data analytics.
- - The project has created a comprehensive platform that integrates various data sources, helping to respond to critical research questions and improve understanding of prostate cancer management at different stages.
- - Despite successes, challenges with real-world data persist, necessitating ongoing collaboration and knowledge sharing, which PIONEER aims to support as part of the UroEvidenceHub initiative by the European Association of Urology.
Article Synopsis
- Duchenne and Becker muscular dystrophy currently have no cure, but the Dutch Dystrophinopathy Database (DDD) aims to facilitate therapy development by gathering comprehensive and reusable data from affected patients.
- DDD allows for online enrollment and participation at varying levels, collecting important clinical and self-reported data while maintaining a governance structure for effective management and oversight.
- As of November 1, 2023, the database has 742 enrolled participants, enabling the identification of potential candidates for clinical studies and supporting ongoing research in the field.
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in the management of this disease stage. However, these therapies come with their fair share of toxicities and side effects. The goal of this observational study is to report drug-related adverse events (AEs), which are correlated with systemic combination therapies for mHSPC.
View Article and Find Full Text PDFResearch protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program.
Int J Surg Protoc
December 2023
Article Synopsis
- Androgen deprivation therapy has been the standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC), but new combination therapies with chemotherapy and targeted agents have shown better results.
- Recent advancements in treatment, including "triplet" therapies, are helping to improve outcomes for patients, although metastatic disease remains a complex clinical challenge.
- This study aims to create and validate a predictive model to assess the risk of symptomatic progression, new treatments, and death in mHSPC patients based on their characteristics at admission.